Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to exploring mast cell biology and developing transformative therapeutic antibodies. Headquartered in Hampton, New Jersey, the company's mission is to pioneer innovative antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients suffering from severe inflammatory, allergic, and autoimmune diseases.

The company's pipeline primarily focuses on monoclonal and bispecific antibodies. Its lead product candidate, barzolvolimab (CDX-0159), is a humanized monoclonal antibody that specifically inhibits the KIT receptor, which is essential for mast cell function and survival. Barzolvolimab is currently under investigation for various mast cell-driven conditions, including chronic urticarias (chronic spontaneous urticaria and cold urticaria), prurigo nodularis, atopic dermatitis, and eosinophilic esophagitis. Additionally, Celldex is developing CDX-622, a bispecific antibody designed to target two complementary pathways to reduce mast cells and inhibit Type 2 inflammatory responses for inflammatory and fibrotic disorders.

In recent news, Celldex Therapeutics completed enrollment for its two global Phase 3 chronic spontaneous urticaria (CSU) trials for barzolvolimab six months ahead of schedule in February 2026, with topline data anticipated in the fourth quarter of 2026 and a Biologics License Application (BLA) submission planned for 2027. Anthony S. Marucci serves as the Co-founder, President, and Chief Executive Officer. As a clinical-stage biotech, the company's market positioning and future trajectory are largely tied to the successful development and commercialization of barzolvolimab, supported by a strong cash position to fund its operations.